Huons Lab, a subsidiary of Huons Global, announced on the 23rd that it has completed domestic patent registration for the production method of ‘Hydifuse’, a human hyaluronidase drug. Human hyaluronidase is an enzyme that breaks down hyaluronic acid under the skin in the human body. It is considered a key element for changing an intravenous injection type drug to a subcutaneous injection type.
Huons Labs explained that it has secured an optimized process to improve the yield of recombinant human hyaluronidase and increase its purity through patented technology. This technology increases the permeability of human subcutaneous tissue, helping the drug to diffuse quickly, and promotes absorption into blood vessels through the skin, thereby maximizing the diffusion effect of anticancer drugs.
Accordingly, it is explained that Hydifuse can be used as a core material of technology that enables a change in formulation from existing intravenous injection to subcutaneous injection. The company also added that Hydifuse alone can be used in various ways, such as reducing subcutaneous pain and swelling and eliminating filler side effects.
Huons Lab added that this patent registration also means that the company has avoided the original hyaluronidase manufacturing method patent registered by Halozyme in the US and Europe. This will be of great help to global pharmaceutical companies that are developing subcutaneous injections of new drugs or biosimilars.
A representative of Hyosung Labs said, “After the domestic human hyaluronidase clinical trial is completed, we plan to apply for formal approval from the Ministry of Food and Drug Safety in June of next year,” and “We will accelerate the development of a subcutaneous injection drug with improved convenience.”
Source: kormedi.com
